Cardiology Department, Cochin Hospital
Paris, 75014, France
NCT Number: NCT02375893
The purpose of this study is to describe the composition of bile acids and the gut microbiota comparing two populations: patients with coronary atheroma and the healthy subjects.
Our hypothesis is based on the demonstration of the anti atherogenic and anti inflammatory effect of certain bile acids, and the role of the gut microbiota in the metabolic regulation.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Observational
Paris, 75014, France
Atherosclerosis is the main cause of cardiovascular diseases which remain the first cause of death worldwide. The prevention of risk factors can reduce the development of cardiovascular diseases. The final goal of our study is to find new protective or new risk factors that can be modulated to reduce the incidence of cardiovascular events.
Gut microbiota and its main metabolite, the bile acids, are implicated in the metabolic regulation. Some bile acids, especially the secondary bile acids, transformed from the primary bile acids by the bacteria of the gut microbiota, are now demonstrated in murine experimental atherosclerosis models, to be anti inflammatory and anti atherogenic molecules.
We want to compare the pool of bile acids and the composition of gut microbiota between the coronary patients and the healthy subjects to identify the potential protective or deleterious bacteria / bile acids.
All patients admitted for a scheduled coronary angiogram will be included, then divided into two groups: coronary or healthy, based on the presence or the absence of atheroma during the coronary angiogram.
Feces and blood samples, and clinical and biological data, will be collected during the patient's hospitalisation. No additional exam will be performed. The blood sample will be collected during the coronary angiogram or during a routine blood test.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Collecting blood and feces samples
Collecting blood and feces samples
Time frame: 8 months
Observational only
Time frame: 8 months
Observational
Assistance Publique - Hôpitaux de Paris
Other
The Official Title is in French: Microbiote, Acides Biliaires et Athérome Coronaire (MABAC)
Acronym: MABAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00064506
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00091754
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00005143
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00880178
Arterial Occlusive Diseases, Arteriosclerosis
Birmingham, Alabama, United States
View Trial Details